3 "We are proud to support Viking Therapeutics with a strong end-to-end offering for their complex modalities, from peptide drug substance to drug product, for VK2735," said Michael Quirmbach, ...

CordenPharma will provide large-scale manufacturing for VK2735 drug substance, and of fill-finish for the subcutaneous formulation and oral solid dosage manufacturing for the oral peptide formulation.

Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its investigational obesity drug, VK2735 ... the oral peptide should be ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for ... of its dual GIP/GLP-1 agonist VK2735. Under the deal, CordenPharma will crank ...

Per the terms, Viking has secured dedicated manufacturing capacity to support the large-scale production of VK2735. The deal includes an annual supply commitment for multiple metric tons of the ...

VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, is being developed in both oral and subcutaneous ...

CordenPharma provides large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance of VK2735. CordenPharma provides fill-finish for the drug candidate's subcutaneous ...

The agreement provides Viking with sufficient long-term supply of both subcutaneous and oral VK2735 product forms to support a potential multi-billion-dollar annual product opportunity.